Dilip Shanghvi

In comparison, Ambani, who topped the list last year, has seen a 2.5 per cent decline in his family's net worth to $101.75 billion from $104.4 billion a year ago

There is a bullish formation of a "Higher High, Higher Low" pattern on the daily chart, and only if the stock breaks the 200-DMA the trend could turn negative.

The rights issue will open on October 11, closing on October 20

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Strong sales in Q4 during war aided by 'stocking up of inventory'

Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal. "We expect high single-digit top-line growth for FY23. All our businesses are positioned for growth. Ramp up in our global speciality business is expected to continue," Sun Pharma Managing Director Dilip Shanghvi said in an analyst call. He noted that markets across the globe were now in the process of normalising. "R&D investments are expected to be between 7-8 per cent of sales next year," Shanghvi noted. On its Halol-based manufacturing plant, he stated that the company will be filing its response to the FDA on the corrective actions to be undertaken to address the observations within the stipulated time. Earlier this month, the US health regulator had issued a ...

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

Sun Pharma Advanced Research Company on Thursday said it has raised over Rs 1,112 crore by way of issuing warrants to the company's promoter Dilip Shanghvi and other entities

Two whistle blowers had alleged that Sun Pharma and its subsidiary Sun Pharmaceutical Laboratories diverted funds through its sole distributor in India Aditya Medisales

Revenues remain flat, sequential improvement in India and US revenues

The company's strategy of developing the Specialty business as an additional growth engine has started delivering, with a gradual ramp up in specialty revenues, Shanghvi said

The Bajaj group is the only one on the list of 12 conglomerates to be down - 1 per cent - since the lockdown came into effect, thanks to the hammering of stocks of non-banking financial companies.

Dilip Shanghvi, the Sun Pharma promoter has 23% in renewable power firm that has failed to get debt recast plan

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications

Shanghvi, one of the lowest-paid CEOs in India's pharmaceutical sector, drew a salary of Rs 1 during 2018-19

Drug major Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock "low-to-mid teens" growth in consolidated revenues in the current fiscal. Addressing shareholders in the company's annual report for 2018-19, Sun Pharma Managing Director Dilip Shanghvi said the company is focused at growing each of its business verticals faster than the market in which it operates. "Our consistent focus is on growing each of our businesses faster than the market in which they operate. Our global specialty initiatives will supplement this objective as an additional growth engine," Shanghvi said. The company is targeting key ailments like psoriasis to gradually ramp up its global specialty business, he said adding that Sun Pharma would continue to invest in branding and promotion of its various specialty products. Besides, R&D investments for funding clinical trials of some of the specialty products are also likely to continue in ...

Shanghvi proved a white knight for Suzlon in 2015 when he bought 23 percent stake for Rs 18 billion

In one of these projects, MJ Pharma's share in profit or loss is 30%, while in the other four projects, it is 37.5%

Shares of Sun Pharma have hit a wall after surging for 20 years

Talking about his business turn over, he said that US is the largest market for his company, adding almost 50% of the turnover is in US